OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
45
Results
Show all
Save search
Copy query
Show results for
Unknown
(44)
Proteomics
(1)
Organisms
Homo sapiens
(1)
Repository
iProX
(1)
Publication Date
2023
(1)
Release Date
2024
(11)
2025
(9)
2023
(8)
2022
(7)
2026
(3)
2020
(3)
2021
(2)
2010
(1)
Previous
page
1 / 5
You're on page
1
page
2
page
3
page
4
page
5
Next
page
Sort
by:
Relevance
Page size
10
A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma.
Not available
S-EPMC9732039
|
biostudies-literature
Cite
Chlorido[4-(pyridin-2-yl-κN)pyrimidine-2-sulfonato-κN,O]palladium(II).
Not available
S-EPMC3011378
|
biostudies-literature
Cite
Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial.
Not available
S-EPMC8895828
|
biostudies-literature
Cite
Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial.
Not available
S-EPMC9795751
|
biostudies-literature
Cite
Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.
Not available
S-EPMC7216554
|
biostudies-literature
Cite
Characteristics and patient-reported outcomes of long-term cancer survivors after apatinib-based therapy: an online survey.
Not available
S-EPMC11366127
|
biostudies-literature
Cite
Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study.
Not available
S-EPMC8753451
|
biostudies-literature
Cite
First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects.
Not available
S-EPMC8866703
|
biostudies-literature
Cite
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.
Not available
S-EPMC12645347
|
biostudies-literature
Cite
Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial.
Not available
S-EPMC7359576
|
biostudies-literature
Cite
Previous
page
1 / 5
You're on page
1
page
2
page
3
page
4
page
5
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets